The S1P receptor 2 (S1P2), also known as endothelial differentiation sphingolipid G-protein-coupled receptor 5 (EDG5), signals through Gi, Gq and G12/13 pathways and has been shown to inhibit cell migration in several cell types. Additionally, many different malignant cells have been shown to overexpress S1P2. For example, S1P2 is expressed in melanoma cells and is co-expressed together with S1P3 in breast cancer cells. Moreover, S1P2 expression has also been found in glioma cells and nine gastric cancer cell lines were shown to express S1P2 to varying degrees. Finally, the S1P2 selective antagonist JTE-013 has been shown to negatively regulate endothelial morphogenesis and angiogenesis. Is this molecule inhibitor of S1P2? The S1P receptor 2 (S1P2), also known as endothelial differentiation sphingolipid G-protein-coupled receptor 5 (EDG5), signals through Gi, Gq and G12/13 pathways and has been shown to inhibit cell migration in several cell types. Additionally, many different malignant cells have been shown to overexpress S1P2. For example, S1P2 is expressed in melanoma cells and is co-expressed together with S1P3 in breast cancer cells. Moreover, S1P2 expression has also been found in glioma cells and nine gastric cancer cell lines were shown to express S1P2 to varying degrees. Finally, the S1P2 selective antagonist JTE-013 has been shown to negatively regulate endothelial morphogenesis and angiogenesis. Can this molecule inhibite S1P2? The S1P receptor 2 (S1P2), also known as endothelial differentiation sphingolipid G-protein-coupled receptor 5 (EDG5), signals through Gi, Gq and G12/13 pathways and has been shown to inhibit cell migration in several cell types. Additionally, many different malignant cells have been shown to overexpress S1P2. For example, S1P2 is expressed in melanoma cells and is co-expressed together with S1P3 in breast cancer cells. Moreover, S1P2 expression has also been found in glioma cells and nine gastric cancer cell lines were shown to express S1P2 to varying degrees. Finally, the S1P2 selective antagonist JTE-013 has been shown to negatively regulate endothelial morphogenesis and angiogenesis. Is this molecule effective to S1P2? The S1P receptor 2 (S1P2), also known as endothelial differentiation sphingolipid G-protein-coupled receptor 5 (EDG5), signals through Gi, Gq and G12/13 pathways and has been shown to inhibit cell migration in several cell types. Additionally, many different malignant cells have been shown to overexpress S1P2. For example, S1P2 is expressed in melanoma cells and is co-expressed together with S1P3 in breast cancer cells. Moreover, S1P2 expression has also been found in glioma cells and nine gastric cancer cell lines were shown to express S1P2 to varying degrees. Finally, the S1P2 selective antagonist JTE-013 has been shown to negatively regulate endothelial morphogenesis and angiogenesis. Is this molecule effective to this assay?